Program
exagamglogene autotemcel
Also written as “CTX001”, “Exa-cel” and “CTX001 With and Without Iron”.
Its studies are mostly in beta-Thalassemia · Anemia, Sickle Cell · Renal Insufficiency, Chronic · Anemia, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vertex Pharmaceuticals | 74 open or running | phase 3since Aug 29, 2018 | Aug 29, 2018 | Jun 6, 2027phase 3 · NCT05329649 |
| Cajal Therapeutics | 22 open or running | phase 1since Oct 22, 2026 | May 5, 2026 | Oct 2027phase 1 · NCT07901933 |
Also a collaborator on its studies: crispr-therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 29, 2018First study: phase 3 study in beta-ThalassemiaNew to Vertex PharmaceuticalsVertex Pharmaceuticals · NCT03655678 · 59 enrolled · United States, Canada, Germany and more
- Nov 9, 2018Phase 3 study in Anemia, Sickle CellVertex Pharmaceuticals · NCT03745287 · 63 enrolled · United States, Belgium, Canada and more
- Dec 20, 2019Phase 3 study in beta-ThalassemiaVertex Pharmaceuticals · NCT04208529 · 160 planned · United States, Belgium, Canada and more
- Apr 7, 20222 phase 3 studiesVertex Pharmaceuticals · NCT05356195, NCT05329649
- Jul 26, 2022Phase 3 study in beta-ThalassemiaVertex Pharmaceuticals · NCT05477563 · 26 planned · United States, Germany, Italy and more
- Jun 23, 2023Phase 3 study in Anemia, Sickle CellVertex Pharmaceuticals · NCT05951205
- May 5, 2026Cajal Therapeutics's first study: early phase 1 study in AnemiaNew to Cajal TherapeuticsCajal Therapeutics · NCT07577817 · 72 planned · Australia
- Oct 22, 2026Phase 1 study in Renal Insufficiency, ChronicCajal Therapeutics · NCT07901933 · 24 planned · Australia
Ahead
- Jun 6, 2027Primary completion: phase 3 study in Anemia, Sickle CellVertex Pharmaceuticals · NCT05329649
- Jun 9, 2027Primary completion: phase 3 study in beta-ThalassemiaVertex Pharmaceuticals · NCT05477563
- Oct 2027Primary completion: phase 1 study in Renal Insufficiency, ChronicCajal Therapeutics · NCT07901933
- Nov 14, 2027Primary completion: phase 3 study in beta-ThalassemiaVertex Pharmaceuticals · NCT05356195
TargetBeta
“B-cell lymphoma/leukemia 11A gene editing negative modulator”ChEMBL 37, by rule
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07901933Renal Insufficiency, Chronic · Australia | 1 | Not yet recruiting | Cajal Therapeutics | Oct 2027 | 24 |
| NCT07577817Anemia · Australia | Early 1 | Recruiting | Cajal Therapeutics | Oct 2026 | 72 |
| NCT05951205Anemia, Sickle Cell | 3 | Withdrawn | Vertex Pharmaceuticals | Dec 31, 2033 | 0 |
| NCT05477563beta-Thalassemia · United States, Germany, Italy and more | 3 | Recruiting | Vertex Pharmaceuticals | Jun 9, 2027 | 26 |
| NCT05356195beta-Thalassemia · United States, Canada, Germany and more | 3 | Active, not recruiting | Vertex Pharmaceuticals | Nov 14, 2027 | 16 |
| NCT05329649Anemia, Sickle Cell · United States, Germany, Italy and more | 3 | Active, not recruiting | Vertex Pharmaceuticals | Jun 6, 2027 | 13 |
| NCT04208529beta-Thalassemia · United States, Belgium, Canada and more | 3 | By invitation | Vertex Pharmaceuticals | Sep 30, 2039 | 160 |
| NCT03745287Anemia, Sickle Cell · United States, Belgium, Canada and more | 3 | Completed | Vertex Pharmaceuticals | Jul 7, 2025 | 63 |
| NCT03655678beta-Thalassemia · United States, Canada, Germany and more | 3 | Completed | Vertex Pharmaceuticals | Nov 13, 2025 | 59 |
How it is read
Names in the registry
- “CTX001”, 6 entries
- “Exa-cel”, 2 entries
- “CTX001 With and Without Iron”, 1 entry
- “CTX001 With Iron”, 1 entry
- “CTX001 Multiple Dose”, 1 entry
Codes read as this program: CTX001.
Conditions, from the studies’ own filings
- beta-Thalassemia, 4 studies
- Anemia, Sickle Cell, 3 studies
- Renal Insufficiency, Chronic, 1 study
- Anemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.